Daily Digest: Last 19 Hours: Aging Brains, Adolescent Risk, and the Slow March of Policy Reform — March 04, 2026
This digest reviews recent findings on cannabis and cognitive aging, highlighting reassuring safety data for older adults. It also addresses adolescent cannabis exposure risks and ongoing policy reform challenges. The focus on cannabis and cognitive…
What a Major Study Reveals About Cannabis Use and Brain Aging
Cannabis use and brain aging is a complex relationship explored in a major study using large biobank datasets. The research suggests initial differences in brain age metrics among cannabis users but no straightforward harmful or protective effects. This…
Pipeline Progress Drives Investor Focus at Agentix – Ad-hoc-news.de
Endocannabinoid system modulators AGTX-2004 and AGTX-2003 are advancing through clinical development, attracting significant investor focus. These cannabinoid-based therapeutics may offer new treatment options pending clinical validation. Clinicians…
Daily Digest: Adolescent Risks and Pharmaceutical-Grade Cannabis Progress
This daily digest highlights pharmaceutical-grade CBD clinical trial development and adolescent cannabis exposure risks. Recent studies emphasize measurable harm from adolescent use. Meanwhile, cognitive aging research offers reassurance for older adults.
New Study Reveals How 35 Years of Excessive Drinking Impacts Brain
This study highlights chronic alcohol use endocannabinoid system disruption and its role in cognitive and psychiatric complications. Long-term excessive drinking dysregulates this system, impacting brain functions. Understanding this helps clinicians…
Daily Digest: Last 9 Hours: Cognitive Safety Signals, Adolescent Risk, and the Regulatory Puzzle That Still Defines Cannabis Medicine — March 03, 2026
This digest highlights age-dependent cannabis cognitive effects and their clinical implications. It addresses adolescent neurotoxicity risks and the regulatory puzzle that complicates cannabis medicine. The focus is on bridging clinical evidence with…
Avecho Biotechnology Hits Milestone in Phase 3 Insomnia Trial
Avecho Biotechnology has reached a crucial milestone in its phase 3 insomnia trial cannabidiol study. This large-scale trial aims to provide robust efficacy and safety data for CBD as a treatment option. Clinicians should monitor this trial as it may…
How Cannabis Transforms Animal Medicine
Cannabinoid therapeutics veterinary medicine offers promising parallels to human treatments, especially for pain and seizure control. Veterinary research helps establish dosing and safety profiles relevant to clinical practice. This emerging field…
Can I Get Pulled Over for Smelling Like Weed in WA? How Cannabis DUI Laws Work
Cannabis DUI laws Washington create unique challenges for patients using THC therapeutically. These laws allow officers to pull over drivers based on the smell of weed alone. Understanding cannabis impairment in Washington is crucial for safe driving and…
Daily Digest: Cannabis and Anxiety Risk in the Long Run — March 03, 2026
This digest reviews new cohort data on cannabis and anxiety risk long term. While cannabis may offer short-term relief, sustained use shows complex anxiety outcomes. Dr. Caplan provides clinical context on these findings.